LU90806I2 - Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptables - Google Patents
Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptablesInfo
- Publication number
- LU90806I2 LU90806I2 LU90806C LU90806C LU90806I2 LU 90806 I2 LU90806 I2 LU 90806I2 LU 90806 C LU90806 C LU 90806C LU 90806 C LU90806 C LU 90806C LU 90806 I2 LU90806 I2 LU 90806I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- ovidrelle
- pharmaceutically acceptable
- acceptable derivatives
- choriogonadotropin alfa
- preparation
- Prior art date
Links
- 229960004681 choriogonadotropin alfa Drugs 0.000 title 1
- 229940088597 hormone Drugs 0.000 abstract 3
- 239000005556 hormone Substances 0.000 abstract 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 abstract 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/548,228 US4840896A (en) | 1983-11-02 | 1983-11-02 | Heteropolymeric protein |
Publications (1)
Publication Number | Publication Date |
---|---|
LU90806I2 true LU90806I2 (fr) | 2001-09-25 |
Family
ID=24187922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU90806C LU90806I2 (fr) | 1983-11-02 | 2001-07-25 | Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptables |
Country Status (9)
Country | Link |
---|---|
US (2) | US4840896A (fr) |
EP (1) | EP0487512B1 (fr) |
JP (6) | JPS61500249A (fr) |
AT (1) | ATE79408T1 (fr) |
DE (1) | DE3485869T2 (fr) |
HK (1) | HK26196A (fr) |
LU (1) | LU90806I2 (fr) |
NL (1) | NL300049I2 (fr) |
WO (1) | WO1985001958A1 (fr) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455282B1 (en) * | 1983-11-02 | 2002-09-24 | Genzyme Corporation | Cells, vectors and methods for producing biologically active TSH |
US5639639A (en) * | 1983-11-02 | 1997-06-17 | Genzyme Corporation | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof |
US4923805A (en) * | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
US5156957A (en) * | 1983-11-02 | 1992-10-20 | Genzyme Corporation | Follicle stimulating hormone |
US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
JPS60145098A (ja) * | 1984-01-09 | 1985-07-31 | Suntory Ltd | 糖付加ポリペプチドの製造法 |
FR2565599B1 (fr) * | 1984-06-08 | 1989-08-25 | Integrated Genetics Inc | Sequence d'adnc codant pour la beta fsh porcine, vecteur la comprenant, beta fsh produite et son utilisation |
WO1986007383A1 (fr) * | 1985-06-04 | 1986-12-18 | Biotechnology Research Partners, Ltd. | Vaccins auto-antigenes |
FI98829C (fi) * | 1986-01-27 | 1997-08-25 | Chiron Corp | Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta |
ATE131532T1 (de) * | 1986-08-13 | 1995-12-15 | Zymogenetics Inc | Expression von biologisch-aktiven pdgf-analogen in eukaryotischen zellen |
JPS63112985A (ja) * | 1986-10-31 | 1988-05-18 | Daicel Chem Ind Ltd | 新規プラスミド |
JPS63112978A (ja) * | 1986-10-31 | 1988-05-18 | Daicel Chem Ind Ltd | エシエリチア・コリ |
JP2769170B2 (ja) * | 1987-12-08 | 1998-06-25 | ザイモジェネティクス,インコーポレイティド | 真核細肪中での同時発現 |
US5260421A (en) * | 1987-12-21 | 1993-11-09 | Applied Research Systems Ars Holding N.V. | Site-directed mutagenesis modified glycoprotein hormones |
US5635475A (en) * | 1987-12-21 | 1997-06-03 | Applied Research Systems Ars Holding N.V. | Site-directed mutagenesis modified glycoprotein hormones and methods of use |
WO1990002812A1 (fr) * | 1988-09-01 | 1990-03-22 | Applied Research Systems Ars Holding N.V. | Procedes de production de gonadotropine et d'hormones super-agonistes tsh |
US5196524A (en) * | 1989-01-06 | 1993-03-23 | Eli Lilly And Company | Fusion reporter gene for bacterial luciferase |
CA2045131A1 (fr) * | 1989-01-11 | 1990-07-12 | Frederic E. Wondisford | Thyrotrophine synthetique biologiquement active et gene clone servant a la produire |
EP0461200B1 (fr) * | 1989-02-21 | 1997-01-22 | Washington University | Formes modifiees d'hormones de reproduction |
US6828125B1 (en) * | 1989-05-10 | 2004-12-07 | Baxter Biotech Technology, S.A.R.L. | DNA encoding fused di-alpha globins and use thereof |
US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
US5240832A (en) * | 1989-06-20 | 1993-08-31 | Genzyme Corporation | Heteropolymeric protein production methods |
NZ237827A (en) * | 1990-04-16 | 1994-03-25 | Strohtech Inc | Pure globin chain or haem-binding fragment thereof and methods for its production |
US6172039B1 (en) | 1990-04-16 | 2001-01-09 | Apex Bioscience, Inc. | Expression of recombinant hemoglobin and hemoglobin variants in yeast |
DE69226197T2 (de) * | 1991-11-08 | 1999-02-11 | Somatogen Inc | Hämoglobine als arzneimittelabgabesystem |
US6737515B2 (en) | 1993-11-19 | 2004-05-18 | Washington University | Follicle stimulating hormone-glycosylation analogs |
US6017697A (en) | 1994-11-14 | 2000-01-25 | Eli Lilly And Company | Excitatory amino acid receptor protein and related nucleic acid compounds |
EP0786523A3 (fr) | 1996-01-29 | 2000-01-12 | Eli Lilly And Company | Kinase de protéine et procédé d'utilisation |
US6162905A (en) * | 1996-11-07 | 2000-12-19 | Ibsa Institut Biochimique S.A. | FSH and LH separation and purification process |
US6476211B1 (en) * | 1998-07-16 | 2002-11-05 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
US7112341B1 (en) | 1999-04-13 | 2006-09-26 | Nektar Therapeutics | Pulmonary administration of dry powder formulations for treating infertility |
US6911204B2 (en) * | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
WO2002013861A2 (fr) * | 2000-08-11 | 2002-02-21 | Favrille, Inc. | Methode et composition de modification d'une pathologie a mediation assuree par les lymphocytes t |
US6824822B2 (en) * | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
CN105131104B (zh) | 2001-10-10 | 2018-11-16 | 诺和诺德公司 | 肽的重构和糖缀合 |
NZ535008A (en) * | 2002-02-08 | 2005-09-30 | Alkermes Inc | Polymer-based compositions for sustained release |
EP1610803B8 (fr) * | 2003-03-04 | 2011-09-14 | AspenBio Pharma, Inc. | LH pour utilisation pour maintenir une ou plusieurs grossesses en induisant la formation du corps jaune secondaire. |
EP2338333B1 (fr) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes |
UA88879C2 (en) * | 2003-09-02 | 2009-12-10 | Эплайд Рисерч Системз Эрс Холдинг Н.В. | Fsh glycosylation mutant |
JP4412989B2 (ja) * | 2003-12-15 | 2010-02-10 | 株式会社日立製作所 | 複数の記憶システムを有するデータ処理システム |
JP2008504012A (ja) * | 2004-01-28 | 2008-02-14 | シントニックス・ファーマシューティカルズ・インコーポレーテッド | 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Fc(FSH−Fc)融合タンパク質 |
AU2005211847B2 (en) | 2004-02-13 | 2011-02-24 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
ATE531374T1 (de) | 2004-04-15 | 2011-11-15 | Alkermes Inc | Vorrichtung auf polymerbasis mit verzögerter freisetzung |
US20060110423A1 (en) * | 2004-04-15 | 2006-05-25 | Wright Steven G | Polymer-based sustained release device |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
KR20080106976A (ko) * | 2006-03-17 | 2008-12-09 | 스템 셀 테라퓨틱스 코포레이션 | 신경 줄기 세포 증식제 및 신경 줄기 세포 분화제의 연속 투여 방법 |
US7682356B2 (en) | 2006-08-09 | 2010-03-23 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
JP5351884B2 (ja) | 2007-04-23 | 2013-11-27 | インターシア セラピューティクス,インコーポレイティド | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
KR101573773B1 (ko) | 2008-02-08 | 2015-12-02 | 바이오제너릭스 게엠베하 | Fsh의 액체 포뮬레이션 |
CA2726861C (fr) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques |
JP5845170B2 (ja) | 2009-04-01 | 2016-01-20 | ラティオファーム ゲーエムベーハー | 組換えfshを精製する方法 |
HUE035862T2 (en) | 2009-09-28 | 2018-05-28 | Intarcia Therapeutics Inc | Rapid development and / or completion of substantially steady-state drug delivery |
TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
EP2325194A1 (fr) | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Processus de purification de glycoprotéines |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
CN103509121B (zh) | 2012-11-22 | 2015-01-28 | 苏州康宁杰瑞生物科技有限公司 | 一种fsh融合蛋白及其制备方法和用途 |
WO2014183175A1 (fr) * | 2013-05-16 | 2014-11-20 | Universidade De São Paulo | Procédés de production et/ou purification d'hormones |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
ES2968262T3 (es) | 2015-06-03 | 2024-05-08 | I2O Therapeutics Inc | Sistemas de colocación de implantes |
WO2017200943A1 (fr) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Polypeptides sélectifs du récepteur du glucagon et méthodes pour les employer |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
CN108264549A (zh) * | 2018-03-29 | 2018-07-10 | 北京伟杰信生物科技有限公司 | 重组绒促性素rhCG的制备方法及应用 |
AU2019359389A1 (en) | 2018-10-10 | 2021-05-27 | Peter T. Falkner | System and method for intrauterine insemination |
BR102019004147A2 (pt) | 2019-02-28 | 2020-10-06 | Ouro Fino Saude Animal Participacoes S.A. | Gonadotrofina coriônica equina recombinante (recg) biologicamente ativa e processo para obtenção da mesma, composição veterinária e uso |
US20220143131A1 (en) | 2019-05-16 | 2022-05-12 | Ceva Sante Animale | Compositions and Methods for increasing Reproduction Performance in Non Human Mammals Using Recombinant Luteinizing Hormone |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4468464A (en) * | 1974-11-04 | 1984-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Biologically functional molecular chimeras |
FR2458584A1 (fr) * | 1979-06-08 | 1981-01-02 | Pasteur Institut | Vecteurs pour le transfert et l'expression de materiel genetique dans une cellule eucaryote et procede pour la production d'une proteine determinee dans des cellules eucaryotes |
US4401759A (en) * | 1980-05-01 | 1983-08-30 | Harvey Rubin | Detection and isolation of glucagon mRNA using a synthetic oligodeoxynucleotide |
JPS586475B2 (ja) * | 1980-08-23 | 1983-02-04 | 株式会社 林原生物化学研究所 | ヒト絨毛性性腺刺激ホルモンの製造方法 |
JPS585671B2 (ja) * | 1980-08-27 | 1983-02-01 | 株式会社 林原生物化学研究所 | ヒト卵胞刺激ホルモンの製造方法 |
US4394443A (en) * | 1980-12-18 | 1983-07-19 | Yale University | Method for cloning genes |
US4419446A (en) * | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4385586A (en) * | 1981-09-04 | 1983-05-31 | Schriever Frederick G | Escape/rescue system |
EP0078154A3 (fr) * | 1981-10-28 | 1985-01-09 | The Regents Of The University Of California | Plasmides et cellules pour l'expression hétérologue de métallothionéines, et procédés pour la production et l'utilisation de métallothionéine |
DE3280392D1 (de) * | 1981-11-23 | 1992-03-26 | University Patents Inc | Steuerung der dna-sequenzen-transkription. |
US4656134A (en) * | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
JPS59501533A (ja) * | 1982-08-10 | 1984-08-30 | ザ トラステイ− オブ コロンビア ユニバ−シテイ− イン ザ シテイ オブ ニユ− ヨ−ク | 蛋白質様物質の製造における真生核促進体連鎖の使用 |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
LU84795A1 (fr) * | 1983-05-09 | 1985-03-21 | Labofina Sa | Genes conferant la resistance de la levure a des herbicides |
US4923805A (en) * | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
-
1983
- 1983-11-02 US US06/548,228 patent/US4840896A/en not_active Expired - Lifetime
-
1984
- 1984-10-31 JP JP59503897A patent/JPS61500249A/ja active Pending
- 1984-10-31 EP EP92200198A patent/EP0487512B1/fr not_active Expired - Lifetime
- 1984-10-31 AT AT85900268T patent/ATE79408T1/de not_active IP Right Cessation
- 1984-10-31 WO PCT/US1984/001766 patent/WO1985001958A1/fr not_active Application Discontinuation
- 1984-10-31 DE DE8585900268T patent/DE3485869T2/de not_active Expired - Lifetime
- 1984-10-31 JP JP59504232A patent/JPH0832244B2/ja not_active Expired - Lifetime
-
1993
- 1993-01-22 US US08/008,233 patent/US5767251A/en not_active Expired - Lifetime
- 1993-06-30 JP JP5162620A patent/JPH06107692A/ja active Pending
-
1995
- 1995-01-26 JP JP7010985A patent/JP2573817B2/ja not_active Expired - Lifetime
- 1995-08-16 JP JP07208877A patent/JP3091673B2/ja not_active Expired - Lifetime
-
1996
- 1996-02-08 HK HK26196A patent/HK26196A/xx not_active IP Right Cessation
-
1999
- 1999-03-16 JP JP11070356A patent/JP3126348B2/ja not_active Expired - Lifetime
-
2001
- 2001-07-20 NL NL300049C patent/NL300049I2/nl unknown
- 2001-07-25 LU LU90806C patent/LU90806I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
DE3485869D1 (de) | 1992-09-17 |
JPS61500251A (ja) | 1986-02-20 |
JPH0832244B2 (ja) | 1996-03-29 |
HK26196A (en) | 1996-02-16 |
JPH11308992A (ja) | 1999-11-09 |
US5767251A (en) | 1998-06-16 |
NL300049I1 (nl) | 2001-10-01 |
JP2573817B2 (ja) | 1997-01-22 |
JPH06107692A (ja) | 1994-04-19 |
JPS61500249A (ja) | 1986-02-20 |
JP3126348B2 (ja) | 2001-01-22 |
WO1985001958A1 (fr) | 1985-05-09 |
JPH0884588A (ja) | 1996-04-02 |
ATE79408T1 (de) | 1992-08-15 |
JPH07203968A (ja) | 1995-08-08 |
EP0487512A1 (fr) | 1992-05-27 |
JP3091673B2 (ja) | 2000-09-25 |
EP0487512B1 (fr) | 1998-08-05 |
NL300049I2 (nl) | 2005-07-01 |
DE3485869T2 (de) | 1993-02-18 |
US4840896A (en) | 1989-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU90806I2 (fr) | Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptables | |
NO941186L (no) | Hormonanaloger med multiple CTP-forlengelser | |
ATE148171T1 (de) | Modifizierte formen von fortpflanzungshormonen | |
LU88738I2 (fr) | Hormone Folliculo-Stimulante humaine recombinante (follitropine alpha) et ses dérivés pharmaceutiquement acceptables GONAL-F | |
IT1232827B (it) | Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle | |
LV10196A (lv) | Olbaltumviela biologiski aktivais hormons olbaltumvielas iegusanas panemiens farmaceitisks preparats | |
ATE88352T1 (de) | Humanes relaxinpraeparat. | |
SE8603228D0 (sv) | Sarlekningsmedel | |
ES2181281T3 (es) | Formulaciones liquidas de interferon beta. | |
JPS539762A (en) | Hydoxyysuccinimideeester derivative* its preparation and method of bonding biologically active proteins | |
DE3571552D1 (en) | Preparation containing stabilized polypeptide having gamma-interferon activity | |
NZ209590A (en) | Gamma interferon analogue, preparation and pharmaceutical composition | |
NZ223043A (en) | Sialic acid derivatives; use as stabilisers for physiologically active substances and as binders in chromatography | |
EP0177342A3 (fr) | Formulations orales de protéines thérapeutiques | |
ES2009215A6 (es) | Procedimiento de preparar un derivado de interleucina-1beta. | |
EP0289572A4 (fr) | Utilisation de proteines de l'interleukine-1 contre l'arthrite. | |
GB1523825A (en) | Induction of ovulation with partially desialylated human chlorionic gonadotropin | |
EP0287075A3 (en) | Process for the construction of an animal cell line for the production of human beta-interferon | |
FI102282B1 (fi) | Menetelmä O-glykosyloidun IGF-1:n valmistamiseksi | |
EP0315118A3 (fr) | ADN codant pour endothéline et son utilisant | |
ATE84221T1 (de) | Arzneimittel mit methylcellulose. | |
ATE100143T1 (de) | Hormone und verfahren zur herstellung, verwendung und pruefung derselben. | |
EP0219839A3 (fr) | Dérivé de l'interleukine-2, sa préparation et utilisation | |
HUT55625A (en) | Hair-restorer comprising animal materials as active ingredient |